Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward
Contraline raised $92.5 million in new funding to advance its two male contraceptive candidates, including a once-daily topical gel and an implantable option.
Trial Data Shows ‘IUD for Men’ Is Effective for 2 Years
Contraline released promising new trial data showing that its male contraceptive gel has demonstrated safety and efficacy in the first two trial participants to reach the two-year mark. The company is aiming to earn the product’s FDA approval by the end of 2028, according to CEO Kevin Eisenfrats.
presented by
The Healthcare Payments Industry Has a Perception Problem
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
MedCity FemFwd: What Male Birth Control Means for Women’s Health
In this episode, we’re joined by Régine Sitruk-Ware, a distinguished scientist at the Population Council’s Center for Biomedical Research (CBR), and Chelsea Polis, senior scientist of epidemiology at CBR. They talk about the effect upcoming male birth control products could have on women's health.
Trial Data Looks Promising for ‘IUD For Men’
Contraline released promising data from the clinical trial it’s conducting to test the efficacy of Adam, its male birth control product. The nonhormonal gel seems to be doing a good job of blocking the flow of sperm to the vas deferens, and no serious adverse events have been reported.
One Step Closer to ‘IUD For Men’: Doctors Inject First Humans with Male Contraceptive Gel
Medical device company Contraline became the first to implant a hydrogel-based male contraceptive gel into humans in a clinical trial. Implanted during a noninvasive 10-minute office procedure, the gel promises to block the flow of sperm to the vas deferens. If proven safe and effective, it could become the first nonhormonal, reversible contraceptive for men on the market.